Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Cisplatin was the first metal-based therapeutic agent approved for the treatment of human cancers, but its clinical activity is greatly limited by tumor drug resistance. This work utilized the parent complex [Ru(phen)(2)(PIP)](2+) (1) to develop three Ru(II) complexes (2–4) with different positional...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Sci Rep
Huvudupphovsmän: Zeng, Leli, Chen, Yu, Liu, Jiangping, Huang, Huaiyi, Guan, Ruilin, Ji, Liangnian, Chao, Hui
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4725915/
https://ncbi.nlm.nih.gov/pubmed/26763798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep19449
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk